JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10<blockquote>摩根大通将Recursion Pharmaceuticals评级从中性上调至跑赢大盘,将PT从10美元调整至11美元</blockquote>
Recursion Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f